Virtual Screening of Potent Inhibitors for *Mycobacterium tuberculosis* Arabinogalactan Synthesis

ABSTRACT

Background: Tuberculosis remains the most prevalent infectious disease, requiring the identification of new targets and drugs due to emerging drug resistance for *My-cobacterium tuberculosis*. Virtual screening has the potential to be highly valuable for identifying new drug candidates by searching through compound databases. The present study involved screening a library of around 3.5 million selected compounds from the ZINC20 database and a reference inhibitor library from literature to identify strong inhibitors against the Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) enzyme of *M. tuberculosis* through virtual methods.

Methods: A two-step selection of compounds was carried out from the ZINC20 database using stringent reference physicochemical ranks based on the reference inhibitor library. The resulting library comprised 2700 compounds from the ZINC database along with 21 reference inhibitors from the literature exhibiting MICs of 10 μ M or lower. Docking simulations were performed for a total of 2721 compounds based on the AutoDock Vina tool using python-based computational drug discovery software, PyRx against the crystal structure of *M. tuberculosis* DprE1 enzyme (Protein Data Bank, PDB: 4P8K).

Results: After docking analysis of the selected final library (2721 in total), we determined 21 molecules as top-ranked compounds. The top-ranked compounds from the ZINC20 library had a Δ G in the range of -11 and -11.9 compared to -7.7 and -10.9 of the selected 21 reference inhibitors with MICs of 10 μ M or lower. Among the whole library, ZINC00009429240 and Ref3 emerged as the highest ranked compounds, exhibiting a Δ G value of -11.9 and -10.9, respectively. ZINC00009429240 and Ref3 were determined to show H-bond interactions with 228S and 418K versus 132H, 228S and 60Y, respectively.

Conclusion: Here, we virtually identified a largely distinct set of compounds as effective inhibitors for the DprE1 enzyme of *M. tuberculosis.* The data gathered in this study may have the potential to be developed into effective drug molecules.

Key Words: Bioinformatics, chemistry, medical microbiology.

INTRODUCTION

Tuberculosis (TB) is among the top 10 leading causes of death on a global scale, with more than 1.5 million deaths and a 10 million annual new diagnosis according to the World Health Organization.¹ Due to the highly contagious nature of TB and its airborne transmission, drug resistant strains become difficult to control. The global efforts for preventing TB includes early detection, vaccination, efficient treatment and surveillance.² Currently, TB treatment consists of four old drugs including pyrazinamide (PYR), isonia-zid (INH), ethambutol (EMB) and rifampicin (RFP) which are applied in combination. The incorrect use of the antibiotics resulted in the development of drug-resistant strains of *M. tuberculosis.*³ The current worldwide strategy to combat drug resistant *M. tuberculosis* strains has been directed towards the development of novel TB drugs, especially those with novel targets.⁴ TB drugs target and inhibit numerous essential pathways involved in cell wall formation (e.g., InhA, KasA, and Emb proteins), ATP synthase, nucleic acid synthesis (via DNA gyrase and topoisomerase IV inhibition), protein synthesis (targeting ribosomal proteins), fatty acid biosynthesis and many others.⁵

Over the past decade, new drugs have been approved for tuberculosis treatment. Some of these drugs target well-known important enzymes like InhA (enoyl-ACP reductase) while others effectively target different mechanisms to inhibit *M. tuberculosis*. Among

CC 0 S

Copyright@Author(s) - Available online at http://trendsinpharmacy.org/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Nurbanu Yaşar¹ D Ahmet Serhat Ayvaz² D Gülay Dilek³

¹Department of Medical Microbiology, University of Mersin, Faculty of Medicine, Mersin, Türkiye ²Department of Pharmaceutical Microbiology, Zonguldak Bülent Ecevit University, Faculty of Pharmacy, Zonguldak, Türkiye ³Department of Pharmaceutical Basic Sciences, Zonguldak Bülent Ecevit University, Faculty of Pharmacy, Zonguldak, Türkiye

Corresponding author: Gülay Dilek

Address: Department of Pharmaceutical Basic Sciences, Zonguldak Bülent Ecevit University, Faculty of Pharmacy, Zonguldak, Türkiye Email address: gulay.dilek@beun.edu.tr

Received: May 29, 2024 Revision Requested: June 6, 2024 Last Revision Received: June 9, 2024 Accepted: June 10, 2024 Publication Date: June 14, 2024

Cite this article as: Yaşar N, Ayvaz AS, Dilek G. Virtual screening of potent inhibitors for *Mycobacterium tuberculosis* arabinogalactan synthesis. *Trends Pharm*. 2024, 1, 9, doi: 10.5152/TrendsPharm.2024.23009 these targets, Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) plays an important role in the biosynthesis of cell wall arabinogalactan. DprE1 is the target of two recently approved antituberculosis drugs, including delamanid (DLM) and pretomanid (PMD). These drugs are being used in the management of extensively drug-resistant TB (XDR TB).⁶

Drug screening aimed at inhibiting the mycolic acid synthesis through the targeting DprE1 has demonstrated significant promise in the development of novel drugs for tuberculosis.⁷⁻⁹ In recent years, computational methods have made it possible for screening of millions of potential drug candidates for the treatment of tuberculosis.¹⁰ In this study, we aimed to evaluate a large-scale of compounds via *in-silico* screening against DprE1 for the discovery of potential drug candidates for TB treatment.

MATERIAL AND METHODS

Construction of Compound Library And Preparation

The compounds used for the virtual screening were collected from the ZINC20 database (https://zinc20.docking.org).¹¹ The physicochemical properties of the DprE1 potent inhibitor library (included ~1519 compounds) from literature¹² were utilized for selecting compounds from ZINC20. The average values comprising standard deviations (SD) of molecular weight (MW), cLogP, H-bond donors, H-bond acceptors, topological polar surface area (TPSA), flexibility, rotatable bonds, druglikeness, and also toxicity properties were calculated from the potent DprE1 inhibitor library. In addition to physicochemical features, the compounds known to have MIC values lower than 10 μ M were also screened for determining a cut-off Gibbs free energy (Δ G, kcal/mol) value.

Selected compounds were chosen from the ZINC20 database based on their purchasability, 3D structures, reactivities, and reference values in the range of 2.5-4.57 for cLogP and 300-500 for MW as the first step of selection. In the second step, these collected compounds underwent evaluation using physicochemical descriptors other than cLogP and MW through Datawarrior v06.01 software.¹³ The reference range values used for selection were 70-120 for TPSA, 0.10-0.25 for flexibility, less than 10 for H-bond acceptors, less than 5 for H-bond donors, greater than 0 for druglikeness, and a range of 2-8 for rotatable bonds; in addition to avoiding high mutagenicity. Thus, the selection ensured compatibility to Lipinski's R05 rule¹⁴ even with some more strict parameters for a more accurate prediction for targeting *M.tuberculosis*.

Virtual Screening

Multiple docking simulations for the compounds selected were performed using the AutoDock Vina tool¹⁵ in python-based computational drug discovery software, PyRx¹⁶ against the crystal structure of *M. tuberculosis* DprE1 enzyme (Protein Data Bank, PDB: 4P8K).¹⁷ The crystal structure used contained a complex with a potent inhibitor, and the active cavity was determined to include the space where the inhibitor interacted. The dimensions of this cavity were as follows: center (x, y, z) = (16, -20, 1.5), and dimensions (x, y, z) = (11, 16, 14). The crystal structure of M. tuberculosis DprE1 enzyme was imported into the software and underwent protein preparation steps including removing unwanted molecules such as water, adding polar hydrogen and charge; then converting the prepared protein to .pdbqt format using PyRx automatically. When preparing the ligands, all selected compounds from ZINC20 and the reference compounds from the literature¹² with minimum inhibitory concentrations lower than 10 μM were imported into PyRx. The integrated OpenBabel module was then used for multiple ligand minimization and conversion to .pdpgt format. Docking simulations for each ligand were run in 8 repetitions to calculate ΔG . After the docking simulations, only docked poses with lower total binding energy compared to those of reference compounds, with a root mean square deviation (RMSD) value \leq 2 Å, and with successful binding in the selected cavity space were accepted as top-ranked compounds. The inhibition constant (Ki) was calculated from the binding energy (ΔG) using the formula: Ki = exp(ΔG / RT) (R is the universal gas constant [1.985 × 10–3 kcal mol–1 K–1] and T is the temperature [298.15 K]). The compounds were visually evaluated using PyMOL Molecular Graphics System.¹⁸ 2D interaction profiles were obtained using Maestro v.11.8.012 of the Schrodinger 2018.4 (Schrodinger, LLC, New York, NY, 2018) Linux Ubuntu (2020) version.

Mutation Screening for the Interacting Amino Acids

DprE1 of *M. tuberculosis* has the potential for amino acid mutations. A mutation screening was conducted specifically for amino acid positions that interacted with reference inhibitors and top ranked compounds. Gene sequences related to DprE1 enzyme were gathered from Genbank (www.ncbi.nlm.nih.gov/genbank/), aligned, converted to amino acid sequences, and compared to the reference DprE1 sequence (NP_218307.1) of *M. tuberculosis* via BioEdit v7.7.1. It was assessed if there were any records of mutations at the positions where the compounds interacted.

RESULTS

In preparing the compound library in the ZINC20 database, we applied five basic selections based on molecular weight, cLogP, 3D structure, in-stock availability, and reactivity properties. The initial selection resulted in the collection and download of approximately 3.5 million compounds (accessed on March 15, 2024) in .sdf format. Subsequently importing the library into Datawarrior software led to a second selection process based on reference value ranges for H-bond donors, H-bond acceptors, topological polar surface area, flexibility, rotatable bonds, druglikeness criteria as well as toxicity properties. This rigorous process yielded a total of 2700 compounds with similar physicochemical descriptors clustering as those found in the potent DprE1 inhibitors' library.¹² Virtual screening involved 2700 compounds from the ZINC20 database and 21 reference inhibitors with a MIC of 10 μ M or lower selected from the inhibitor library. The inhibitors with the highest MICs reported a ΔG in the range of -7.7 and -10.9. Ref3 showed the strongest interaction among the selected 21 inhibitors in the reference inhibitor library, with a ΔG of -10.9. A total of 21 compounds from the ZINC20 library were identified as top-ranked ones, exhibiting lower binding energies than those of Ref3. The top-ranked compounds from the ZINC20 library had a ΔG in the range of -11 and -11.9. Within these, ZINC000009429240 was found to be the top-ranked compound with a ΔG of -11.9. From the 2D interaction maps of the top-ranked compounds of the reference and the ZINC20 library, H-bond interactions with 228S and 418K versus 132H, 228S and 60Y; hydrophobic interactions with 116P, 131I, 316P, 365V and 415Y versus 116P, 316P and 365V were determined for ZINC000009429240 and Ref3, respectively (Figure 1). Amino acids positions of 228S, 116P, 316P and 365V were found to be common

positions that interact with both ZINC000009429240 and Ref3. The names, structures as SMILE format, binding energies, and Ki values of reference compounds (with MICs lower than 10 μ M) as well

as the top-ranked 21 compounds of the library from the ZINC20 database are given in Table 1.

. Energies and	Inhibition Consta	nt (Ki) Values	of Top-Ranked	d Compounds fro	m Reference ¹² a	nd ZINC20 Libraries
•	. Energies and	. Energies and Inhibition Consta	. Energies and Inhibition Constant (Ki) Values	. Energies and Inhibition Constant (Ki) Values of Top-Ranked	. Energies and Inhibition Constant (Ki) Values of Top-Ranked Compounds fro	. Energies and Inhibition Constant (Ki) Values of Top-Ranked Compounds from Reference ¹² a

Compound name	SMILES	Binding energy (∆G, kcal/mol)	Ki (µM)
Ref01	c1cc[ccc10C2CCN[CC2]c3nc[=0]c4cc[cc[c4s3]N[=0]=0]C[F][F]F]F	-9,7	0,076
Ref02	c1cc[ccc1C[=0]0C2CCN(CC2)c3nc[=0]c4cc[cc[c4s3]N[=0]=0]C[F][F]F]F	-10,7	0,014
Ref03	c1c(cc(c2c1c(=0)nc(s2)N3CCN(CC3)NC4CCCCC4)N(=0)=0)C(F)(F)F	-10,9	0,010
Ref04	c1c(cc(c2c1c(=0)nc(s2)N3CCN(CC3)NCC4CCCC4)N(=0)=0)C(F)(F)F	-10,4	0,023
Ref05	c1ccc(cc1)c2nnc(n2C3CCCCC3)SCc4cc(cc(c4)N(=0)=0)N(=0)=0	-9,9	0,054
Ref06	CCCCCCn1c(nnc1SCc2cc(cc(c2)N(=0)=0)N(=0)=0)c3ccccc3	-9	0,249
Ref07	CCCCCCn1c(nnc1SCc2ccccc2)c3cc(cc(c3)N(=0)=0)N(=0)=0	-8,3	0,812
Ref08	c1c(cc(c2c1c(=0)nc(s2)N3CCC4(CC3)SCCS4)N(=0)=0)C(F)(F)F	-8	1,347
Ref09	C0c1cc2c(cc10C)CN(CC2)c3nc(=0)c4cc(cc(c4s3)N(=0)=0)C(F)(F)F	-9,5	0,107
Ref10	COc1ccc[cc1]Cn2c[nnc2SCc3cc[cc[c3]N[=0]=0]N[=0]=0]c4ccccc4	-9,7	0,076
Ref11	FC1=CC=C(0C2CCN(CC2)C(=0)C2CCN(CC2)C2=CC(=NC=N2)N2CC0CC2)C(F)=C1	-9,3	0,150
Ref12	c1ccc(cc1)c2nnc(n2c3ccc(c(c3)Cl)Cl)SCc4cc(cc(c4)N(=0)=0)N(=0)=0	-10,6	0,017
Ref13	c1ccc(cc1)Cn2c(nnc2SCc3ccc(cc3)Br)c4cc(cc(c4)N(=0)=0)C(F)(F)F	-9,9	0,054
Ref14	c1c(cc(c2c1c(=0)nc(s2)N3CCOCC3)N(=0)=0)C(F)(F)F	-9,2	0,177
Ref15	0=C(N1CC(C2=C(F)C=C(F)C=N2)=0)C(C3=CC=C(C#N)C=C3)(C)NC1=0	-9	0,249
Ref16	0=C1N(C(C(N1)(C2=CC=C(C#N)C=C2)CC)=0)CC(C3=CC=C(C=C3F)F)=0	-9,4	0,127
Ref17	0=C(N1CC(C2=CC=CC(C)=C2)=0)NC(C3=CC=C(S(=0)(N)=0)C=C3)(C)C1=0	-9,7	0,076
Ref18	0=C(N1CC(C2=CC=CC(F)=C2)=0)NC(C3=CC=C(S(=0)(N)=0)C=C3)(C)C1=0	-8,6	0,489
Ref19	0=C1C2=CC(C(F)(F)F)=CC(N3C(C)=CC=C3C)=C2SC(N4CCN(CC5CCCCC5)CC4)=N1	-8,7	0,413
Ref20	0=C(NC1=C(C(NC(0CC)=0)=0)C=CS1)C2=CC=C(C(N3CCCCC3)=0)C=C2	-10,2	0,033
Ref21	c1c(cc(c2c1c(=S)nc(s2)N3CCN(CC3)CC4CCCCC4)N(=0)=0)C(F)(F)F	-8,8	0,349
ZINC000009429240	Cn1c(=0)c2c(-c3ccccc3)n3c(c2n(C)c1=0)[C@H](c1coc2cccc2c1=0)0CC3	-11,9	0,002
ZINC000021787978	Cc1cccc(-c2c3c(=0)n(C)c(=0)n(C)c3c3n2CC0[C@H]3c2coc3cccc3c2=0)c1	-11,8	0,002
ZINC000021787983	Cc1cccc(-c2c3c(=0)n(C)c(=0)n(C)c3c3n2CC0[C@@H]3c2coc3ccccc3c2=0)c1	-11,7	0,003
ZINC000252672778	CCCCN1C[=0]C[=c2sc3n[c2=0][C@@H][c2ccccc2]C[C[=0]0C]=C[C]N=3]c2ccccc21	-11,6	0,003
ZINC00000632944	0=C1/C[=c2\sc3nc4ccccc4n3c2=0]c2ccccc2N1Cc1ccccc1	-11,5	0,004
ZINC000013775581	0=C1/C(=c2/sc3nc4ccccc4n3c2=0)c2ccccc2N1Cc1ccccc1	-11,5	0,004
ZINC000101343925	0=C(Nc1ccccc1)[C@@H]1[C@@H]2C(=0)N(c3ccc4c(c3)0C04)C(=0)[C@@H]2[C@H]2c3ccccc3C=NN21	-11,5	0,004
ZINC000252517668	0=C(Nc1ccccc1)[C@@H]1[C@@H]2C(=0)N(c3ccc4c(c3)0C04)C(=0)[C@H]2[C@@H]2c3ccccc3C=NN12	-11,5	0,004
ZINC000252669789	0=C1C(=c2sc3nc4ccccc4n3c2=0)c2ccccc2N1Cc1ccccc1	-11,5	0,004
ZINC000002788016	Cc1nn(C)cc1/C=c1\sc2n(c1=0)[C@H]1c3ccccc30[C@@](C)(N=2)[C@@H]1C(=0)Nc1ccccc1	-11,2	0,006
ZINC000008455064	Cc1ccccc1NC(=0)[C@@H]1[C@H]2c3ccccc30[C@]1(C)N=c1s/c(=C/c3cnn(C)c3C)c(=0)n12	-11,2	0,006
ZINC000101455637	CC(=0)N1N=C(c2c(0)[nH]c(=0)n(-c3cccc(Cl)c3)c2=0)C[C@@H]1c1c[nH]c2ccccc12	-11,2	0,006
ZINC000101765650	CCC(=0)N1N=C(c2c(0)[nH]c(=0)n(-c3cccc(Cl)c3)c2=0)C[C@@H]1c1c[nH]c2ccccc12	-11,2	0,006
ZINC000016033791	Cc1cc[C]cc[N2C[=0][C@@H]3[C@@H](Cc4ccc[0]cc4]N[C@]4[C[=0]Nc5ccc[F]cc54)[C@@H]3C2=0]c1	-11,1	0,007
ZINC000019960761	COc1ccc2[nH]c3c(c2c1)CCN1C(=0)c2cnc(N4CCCCC4)nc2C[C@H]31	-11,1	0,007
ZINC000020760244	CC(C)[C@H]1N[C@@]2(c3ccccc3-n3c2nc2cccc2c3=0)[C@H]2C(=0)N(c3ccccc3)C(=0)[C@H]21	-11,1	0,007
ZINC000101765646	CCC(=0)N1N=C(c2c(0)[nH]c(=0)n(-c3cccc(Cl)c3)c2=0)C[C@H]1c1c[nH]c2ccccc12	-11,1	0,007
ZINC00000988062	Cn1c(=0)c2c(nc3n(-c4ccccc4)nc(C(=0)c4ccc5ccccc5c4)n23)n(C)c1=0	-11	0,008
ZINC000013575113	Cn1c(=0)c2c(-c3ccccc3)n3c(c2n(C)c1=0)[C@@H](c1coc2ccccc2c1=0)0CC3	-11	0,008
ZINC000035538889	CN1C(=0)[C@@H](c2c(-c3ccc4cccc4c3)[nH]c3[nH]c(=0)[nH]c(=0)c23)c2ccccc21	-11	0,008
ZINC000252517669	0=C(Nc1ccccc1)[C@@H]1[C@@H]2C(=0)N(c3ccc4c(c3)0C04)C(=0)[C@H]2[C@H]2c3ccccc3C=NN12	-11	0,008

The compounds with lowest ΔG from reference and ZINC libraries were indicated as bold.

The amino acid library containing 100 sequences of DprE1 mostly from diverse strains did not reveal any mutation profiles in amino acids interacting with compounds ZINC000009429240 and Ref3.

The prepared mutation library of DprE1 is included in the Supplementary Figure 1.



DISCUSSION

In the current study, virtual screening was performed using molecular docking with the ZINC20 database¹¹ to search for potent inhibitors against the DprE1 enzyme of *M.tuberculosis* and compared with DprE1 inhibitors reported in the literature.¹² The analysis identified 21 compounds with a binding energy range of -11 to -11.9 as the top-ranked molecules. Both ZINC000009429240 and Ref3 demonstrated a strong interaction with the enzyme cavity, exhibiting a ΔG of -11.9 and -10.9, respectively. These interactions involved H-bonding with amino acid positions of 228S and 418K versus 132H, 228S and 60Y, and hydrophobic interactions with 116P, 131I, 316P, 365V and 415Y versus 116P, 316P and 365V for ZINC000009429240 and Ref3, respectively. Additionally, it was observed that the amino acids at positions of 228S, 116P, 316P and 365V played an important role as they interacted with both ZINC000009429240 and Ref3. When compared with the prepared mutation library of DprE1, it turned out that these interacting amino acids were not affected by mutations in the enzyme.

In recent years, various proteins of *M.tuberculosis* have been targeted for screening of novel and potent inhibitors through various compound databases. The target proteins involved in various studies were DprE1,¹⁹ adenylating enzymes of AspS and KatG,²⁰ protein kinase B (PknB),²¹ glutamine synthetase (GS) in the nitrogen metabolism and cell wall synthesis,²² β-ketoacyl-acyl carrier protein KasA,²³ malonyl Co-A acyl carrier protein transacylase (FabD),²⁴ 7,8-diaminopelargonic acid synthase (BioA),²⁵ and many others. Among these target proteins, DprE1 is particularly important due to its essential role in the synthesis of arabinogalactan and lipoarabinomannan, which are crucial components in mycobacterial cell wall biogenesis.26

Zgang et al.,²⁶ identified potential inhibitors from a virtual screening of 135,755 selected molecules in the ChemDiv dataset, which is also linked to the ZINC database. ZINC09833455 and ZINC32996629 were determined as hit compounds to inhibit DprE1. Due to their availability, certain compounds labeled as "for sale", but not "in stock", and the compounds outside the specified range of physicochemical descriptors such as TPSA and/or logP were excluded from this study. Kumar et al.,¹⁹ conducted a virtual screening of bioactive molecules from the ChEMBL database against DprE1. They identified 4 compounds (ChEMBL2441313, ChEMBL2338605, ChEMBL441373, ChEMBL1607606) as potential inhibitors. However, these were excluded in this study because their molecular weights fell outside the specified range. Anand et al.,²⁷ once again utilized the ZINC database for virtual screening against a modeled DprE1 enzyme, screening a total of 19,365 molecules and identifying the top 10 hit molecules (ZINC06142089, ZINC18116975, ZINC00856140, ZINC01800489, ZINC06142069, ZINC06142038, ZINC03953443, ZINC01886310, ZINC01750499, ZINC11582332) with docking scores ranging from -5.8 to -8 kcal/ mol. These compounds were not included in our library, possibly due to their mutagenicity characteristics. However, the docking scores for these compounds are lower than those of our hit molecules (-11 and -11.9) in the ZINC20 database. According to ZINC20, PubChem (https://pubchem.ncbi.nlm.nih.gov) and Pubmed (https://pubmed.ncbi.nlm.nih.gov) databases (accessed on March 30, 2024), none of the top-ranked compounds of ZINC20 have been reported as potential inhibitors of DprE1.

It's important to note that there is no consensus approach for

virtual screening and thus docking scores can vary for the same compounds and targets. Additionally, although the DprE1 enzyme has been an important target in virtual screening studies, none of them contain a selective library based on physicochemical properties of DprE1 inhibitors known from *in-vitro* data in the literature. Despite high binding affinity data obtained from various virtual screening studies, enabling these hit molecules to penetrate the highly complex cell wall of *M. tuberculosis* may require more stringent physicochemical features which could enhance their efficiency when tested in-vitro. Virtual screening is becoming increasingly important to discover new compounds that will inhibit essential molecules of *M. tuberculosis*. Data obtained from virtual screening has the potential to develope drug-like compounds into potent drug molecules.

CONCLUSION

Overall, we suggested a mostly diverse group of compounds as potent inhibitors of the DprE1 enzyme of *M. tuberculosis.* It would be highly interesting to evaluate the effectiveness of these hit compounds *in-vitro* to validate our approach further. The data gathered in this study may have potential to be developed into effective drug molecules.

Ethics Committee Approval: Ethical approval was not necessary due to the totally in-silico design of the study.

Informed Consent: Informed consent was not necessary due to the totally in-silico design of the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – N.Y., S.A., G.D.; Design – N.Y., S.A., G.D.; Data Collection and/or Processing – N.Y., S.A., G.D.; Analysis and/or Interpretation – N.Y., S.A., G.D.; Writing – N.Y., S.A., G.D.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: The authors declared that this study has received no financial support.

References

- Salina EG. Mycobacterium tuberculosis infection: Control and treatment. *Microorganisms*. 2023 Apr 18;11(4):1057. [Crossref]
- Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020 Reflections on the Global tuberculosis report 2020 Reflections on the global TB burden, treatment and prevention efforts. *Int J Infect Dis.* 2021;113 Suppl 1(Suppl 1):7-12. [Crossref]
- Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens *Nat Rev Drug Discov.* 2013 May;12(5):388-404. [Crossref]
- Singh V, Chibale K. Strategies to combat multi-drug resistance in tuberculosis. *Acc Chem Res.* 2021 May 18;54(10):2361-2376. [Crossref]
- Oh S, Trifonov L, Yadav VD, et al. Tuberculosis drug discovery: a decade of hit assessment for defined targets. *Front Cell Infect Microbiol.* 2021;11:611304. [Crossref]
- Abrahams KA, Batt SM, Gurcha SS, et al. Dpre2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid. *Nat Commun.* 2023;14(1):3828.

[Crossref]

- MakarovV, NeresJ, Hartkoorn RC, et al. The 8-pyrrole-benzothiazinones are noncovalent inhibitors of Dpre1 from mycobacterium tuberculosis. *Antimicrob Agents Chemother*. 2015;59(8):4446-52. [Crossref]
- Tiwari R, Miller PA, Chiarelli LR, et al. Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired. by BTZ043. ACS Med Chem Lett. 2016;7(3):266-270. [Crossref]
- 9. Chikhale R, Menghani S, Babu R, et al. Development of selective Dpre1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. *Eur J Med Chem.* 2015;96:30-46. [Crossref]
- 10. Naidu A, Nayak SS, Lulu S S, et al. Advances in computational frameworks in the fight against TB: The way forward. *Front Pharmacol.* 2023;14:1152915. [Crossref]
- Irwin JJ, Tang KG, Young J, et al. ZINC20-A free ultralarge-scale chemical database for ligand discovery. *J Chem Inf Model.* 2020;60(12):6065-6073. [Crossref]
- Amado PSM, Woodley C, Cristiano MLS, et al. Recent advances of Dpre1 inhibitors against mycobacterium tuberculosis: Computational analysis of physicochemical and ADMET properties. ACS Omega. 2022;7(45):40659-40681. [Crossref]
- Sander T, Freyss J, von Korff M, Rufener C. Datawarrior: An open-source program for chemistry aware data visualization and analysis *J Chem Inf Model*. 2015;55(2):460-473. [Crossref]
- Benet LZ, Hosey CM, Ursu O, et al. BDDCS, The rule of 5 and drugability. *Adv Drug Deliv Rev.* 2016 Jun 1;101:89-98. [Crossref]
- Trott O, Olson AJ. Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem.* 2010;31(2):455-461. [Crossref]
- Dallakyan S, Olson AJ. Small-molecule library screeningby docking with pyrx. *Methods Mol Biol.* 2015;1263:243-50. [Crossref]
- Neres J, Hartkoorn RC, Chiarelli LR, et al. 2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of Dpre1. ACS Chem Biol. 2015;10(3):705-14. [Crossref]
- Schrödinger L, DeLano W. PyMOL. 2020. Retrieved from http://www.pymol.org/pymol
- Niranjan K, Srivastava R, Prakash A, et al. Virtual screening and free energy estimation for identifying mycobacterium tuberculosis flavoenzyme Dpre1 inhibitors. J Mol Graph Model. 2021;102:107770. [Crossref]
- Collins AP, Abdelfattah W. Structure-based virtual screening of essential mycobacterium tuberculosis enzymes AspS and KatG for potential inhibitors. *Bioinformation*. 2021;17(1):101-108. [Crossref]
- Thongdee P, Hanwarinroj C, Pakamwong B, et al. Virtual screening to identify novel potential inhibitors for glutamine synthetase of mycobacterium tuberculosis. PknB with Antibacterial Activity. *J Chem Inf Model.* 2022;62(24):6508-6518. [Crossref]
- Kumari M, Subbarao N. Virtual screening to identify novel potential inhibitors for glutamine synthetase of mycobacterium tuberculosis. *J Biomol Struct Dyn.* 2020;38(17):5062-5080.
 [Crossref]
- 23. Andrianov AM, Furs KV, Gonchar AV, et al. Virtual screening and identification of promising therapeutic compounds against drug-eesistant mycobacterium tuberculosis B-ketoacylacyl carrier protein synthase I (KasA). *J Biomol Struct Dyn.* 2023:1-13. [Crossref]

- 24. Sundararajan S, Karunakaran K, Muniyan R. Structure based virtual screening and discovery of novel inhibitors against FabD protein of mycobacterium tuberculosis. *J Biomol Struct Dyn.* 2023:1-12. **[Crossref]**
- 25. Singh S, Khare G, Bahal RK, et al. Identification of mycobacterium tuberculosis BioA inhibitors by using structure-based virtual screening. *Drug Des Devel Ther.* 2018;12:1065-1079.

[Crossref]

- Zhang G, Guo S, Cui H, et al. Virtual screening of small molecular inhibitors against DprE1. *Molecules*. 2018;23(3):524.
 [Crossref]
- 27. Anand R. Identification of potential antituberculosis drugs through docking and virtual screening. *Interdiscip Sci.* 2018;10(2):419-429. [Crossref]

7		10 10	05	107	10 N	20	10 00	100	10	120	110	140 140	1 AD	110 150	100	100	100 01	140
COCP & Chair & December 1	LEVEALTT	ATTL TOWOD, AND SA	KANTERDERE DATE THEY.	VALUE SOODS	ACAEARCL CLUTCHAM	THIRDWICK TOODS?	THIS DEAD THE VOID	NONSEED-1323ALPD	COLUMN TO	THURSDALDGINGVALDS	VCCALACDURGNOD	TRACTORIZATION IN CARDIN	LACOLIZIC TOTOLO	ARL WATTOOS OL T	CI INCATIZNET S	STAVY DADUDVIASI	LOUT AL ISDUST AT THE	TYPE ALSAPPEL C
STON A Chain A unitered.																		
SUTVA CHARADERPRES																		STATES AND
W PRESERVED AUGUST							· · · · · · · · · · · · · · · · · · ·		120									
THE PARTY OF THE PARTY AND																		
The state of the s																		
A BY AT 14 1 and and and and																		
TOTAL TOTAL CONTRACTOR																	4	
TWP ESTORETSE L decement																		A
NEW CASH OF TAKENER																		-
Two 1521315441, decipert										Construction of the second sec		Contraction of the						
UNICAT INVOLVE COM												State State State State State						100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
The second of the second secon									and in such		100 million and a second secon							
TOTAL STREET, AND STREET									-					1				
THE PROPERTY OF THE PROPERTY O																		
TATA DE LE									-									
W7 031 733164 1 40 400									-									
TATE TOTAL CALLER CALLER									and a second									Turney
「日本市にあったいにしつころへん」									-						. Y			- I I I I I I I I I I I I I I I I I I I
TVD-057319174.1 decement																		Contraction of the
WP 25505204 doupont													Marrison and an and a second					
The sound state and the second									1									
STILLING CLOSEDORE SW																		
UNITED TO RECEIPTION OF THE PARTY OF THE PAR									-									
The later is the second second		A REAL PROPERTY AND A REAL PROPERTY.		And a state of the						Contract of the second state	and the second second second							
ATTRACTOR OF TAXABLE ATTRACT																		
internet of the second second														·				
5.0.000 00 1 00 00 00 00 00 00 00 00 00 00 0																		
The local sector of designer.			********************															いたいというないないです。
APPENDESSESSESSEE																		Same and the
The coll Date of the sectorer		a service of a service of a service of			and the second s			The second secon										
UNUSCIENT ORDER DOUGH								· · · · · · · · · · · · · · · · · · ·										
CICLERIDED endowersen																		
N.2-151 145514 . docaract																		
C10054245.1 oc doments																		
THE REAL PROPERTY AND THE PARTY OF	0																	
NECKLER TO LOCACION																		
TVP 051132024.2 decement				Contraction of the second					-									and the second s
TAP SECTORE TO BE SHOWN				R					1									
TWP-ISTOPTISMU deciprent																		
TUTP 651316014 1 doctored									-									
W7-0511052011 deciport.				ALL CONTRACTOR	十十十十十 人をもちくる あいちき	「「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」			「ないいない	「「」」」、「」」」」」」、「」」」」				·大山山 大山王王 · · · · · ·				
* KN800 81 00 00 00000																		Strate and Strategy
CICCOLOUR CONSTRUCT																		
Careforde 1 1/204001 (2017)								p										
The state of the s								IN										
And the second s																		
The second secon	-																	
THE REAL PROPERTY OF THE AVE																		
The state of the s																P		
And a statement of the																		
NUMBER OF THE OWNERS OF THE OW																		
WP-0501754711. decement									-									
TVD-07163011201 dvcreaker																		Concorrection of
TWP 31 T158554.1 decepter.				And a strength of the strength					A	and a second sec	and a state of the							
106 A Cross A Decrees									-	-								
CUVJS201 1 Children datacan				ALL					Contraction of the local distance of the loc		A DESCRIPTION OF THE OWNER OWNER OF THE OWNER OWNER OF THE OWNER			なないたちとしていたか				222224 A 1222 A 122
Charles of the second second second																		
internet of the second second																		
The state of the s						n n												
THE OTHER DESIGN TO THE PARTY OF THE PARTY O																•		
The second of the second second								DD D										
Statement of the statem								0										
The second construction of the second	13																	
Statement of the statement of the																		
AVERAGE TRACK	N																	
The second is the second second	0									0	4							
The second secon																		
A REAL PROPERTY AND A REAL																		
Sundary S	Ŭ t		$A_1 + 0 + i \\ 0 \\ 0 \\ 1 \\ 1 \\ 0 \\ 0$	i p c p c i				+ []]]] +		(+)	Cod from			トン きてしく	ц С			
anddhc		Sure -	נותומנוסוו ה	u bi ai y					5 1 0					UEGIL V./	N.V			

	1140	250	260	270	280	200	300	310	320 3	30 34	05E 0	360	045	380	055	* 00+	10 +20	430
SUIT A Chain A Decrease	SLORAA	V23.03LATVE	CLPAKLASED	TKPDAPQLLY	TONDANCOT	INVIE OF LOEL	A YRX SOT YROKY	VCNL TQPYHPLE	CAPOENNEAYO	PAGP1CYQBV1	PTEAVDEPEK	IOVICASOHYS	SPLINVPKL FOOP	NQAPL SEP IPCU	NICYDED IXDOL	OKSV38LDRRVL	EPOORL VTAKDSRT1	AE TURANEUR
SELEN A COMPANY OLDORY																		
TTTV LOBOCHEUM TW	k																	
WD 1687387801 deceme			Contraction of the second		and a state of the second		and a second sec						The statement of the st				Construction of the second sec	
WP 220019913.1 decreek																		
4000 A CLER A Provint	100																	
AAKAS255.1 ontdoeddor							and a second second											
CICALT 602.1 cui doreduci																		
WP OUTDOWING A MORE AND A MORE AND A																		
WD 152338548.1 decrease																		····· 4
WP 2144624841 FAD 4W	40 at		A STANDARD STAND															Sector States
WD 0817478141 decrease			······															*********
WP 0094950171 040496																		
ALTER LOCATED AND LOCATED AND	1																	
WT 0573417191 decrees	1 5						10											
WP 031733164.1 decepted			Concession of the second secon		A STATE OF						N					Contraction of the second second		
WP 107199439.1 decages	and a																	
W/D 0167105451 deceme													キャー・キャー かんちょう			ALCONDON CONTRACTOR		*********
WP 0573191241 04090																		
Approx 1 Contractor VV	i l																	
TTIM I VERSEDON UM	12																	
WP 105537301.1 decepter					and a subscription of the													
WP 142902706.1 decises				A a a a a a a a a a a a a a a a a a a a														Contraction of the
CNU37354.1 ecologication																		
Manual 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1																		
Democracy 1 (101711110) 010	91																	
CONTRACTOR 1 02 00 100 100 UM	1																	
WP 051724593.1 decement																		
CINTURS 43.1 anidomotion	No.																	
CKL 89106.1 oxidoreduct.						「なんちろうちちちち					A REAL PROPERTY AND		こう ちょうちょう ちょうろう				いたち ちちちち ちちちち ちちちちちち	
WP 0617495341 deciges	200															and and a second		
CK054545.1 ecidemotic																		and and a state of the
NETADAR CONTRACTOR AND																		1
WP 0517576 1 American	54									I			and the second se					and the second second
M-CIAT LTEOSEEDOL TW	te																	
WD 031697794.1 deceme			The subscription of the				Contraction of the second	· · · · · · · · · · · · · · · · · · ·								and a second sec		
WP 0573160241 decapte	······································																	
W/P 061706803.1 decapes																		
Churchen 1 and																		
WP 0516964011 deceme																		
CICN97216.1 ecidereduct	No.																	Constant of
WD 072400037.1 decepted	13												Contraction of the local division of the loc		Contraction of the second			
WP 0153552251 deciges																		
AND DESCRIPTION OF A DESCRIPTION OF A																		
WD 0515479581 do 2000	1														10			
CE231920.1 enidoredacta		Contraction of the second		and a second	all a second sec	Contraction of the local distance of the loc	Constant of the second second	and a second sec	and the second second				and a second second			Contraction of the second second		
WTP 310905325.1 deciges	2 Mar																	-
CKO60378.1 endewdact											and and and an						and a second sec	
WE STITESTICS IN THE PARTY STATESTICS	1																	
WP 317755654.1 decepter																		
SOELA Chain A Decrete	1																	
CDV39511.1 condoradart																		
WP 103055458.1 decement																		
WP 051741024.1 decages																		- Contraction of
CKL 84561.1 oxidoreduct.																		
WP 057140012.1 decapa-						大学をやたちというです。												Construction -
CXX806161 enderstart	18																	
WTP 055352028.1 deciges	- Jan																-	(and a manual of
WD 055366155.1 decepter																	" Anna and a second sec	
DAW 1900 1-004 BANK	200																	
WP 252159798.1 decrement	1																	
AEMS708.1 oxidoreducta		Contraction of the other	S. S	Number of Street, Stre		A CONTRACTOR OF	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	A Charles of the second		2000 A 100 A 10	1.	a la su a la su a la su a su a su a su a	and the second se			and the second second	A TANK A TANK A DATA	A Share and a share of the
Supplemen	nt Figu	ure 1. M	utation	Library	of DorE1	Gene (c	overing p	oositions	1 to 430)) Obtair	ned from	Genban	k Using E	3ioEdit v.7	7.1 (cont			
				,))					